Perha Pharmaceuticals SAS

Where the EU money came from

Funding by EU programme. Amounts are Perha Pharmaceuticals SAS's own share of each project, not the project's full budget.

Projects

2 EU-funded projects, newest first. Perha Pharmaceuticals SAS led 1 of them as coordinator. Each links to the official record.

• DOWN-AUTONOMYCoordinator

  LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.

  Horizon Europe · 2022–2026 · Project on CORDIS ↗

  €2.5Mtheir share
• GO-DS21Partner

  Gene overdosage and comorbidities during the early lifetime in Down Syndrome

  Horizon 2020 · 2020–2025 · Project on CORDIS ↗

  €200ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

• The Chancellor Masters and Scholars of the University of CambridgeUnited Kingdom · 1 shared project
• King'S College LondonUnited Kingdom · 1 shared project
• Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt GmbHGermany · 1 shared project
• Queen Mary University of LondonUnited Kingdom · 1 shared project
• Fundacio Centre de Regulacio GenomicaSpain · 1 shared project
• Centre Europeen de Recherche en Biologie et en MedecineFrance · 1 shared project
• Institut du Cerveau et de la Moelle EpiniereFrance · 1 shared project
• Fundacio Institut Hospital del Mar D Investigacions MediquesSpain · 1 shared project
• Concentris Research Management GmbHGermany · 1 shared project
• Institut Jerome LejeuneFrance · 1 shared project
• Trisomy 21 Research SocietyNetherlands · 1 shared project

Fields it works in

Research fields recorded on its Horizon projects.

• obesity
• pharmaceutical drugs
• proteins